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Abstract
Background: Clinical outcomes of spontaneous bacterial peritonitis (SBP) due to extended-spectrum β-
lactamase-producing Escherichia coli and Klebsiella species (ESBL-EK) have not been adequately investigated.
Methods: We conducted a retrospective matched case-control study to evaluate the outcomes of SBP
due to ESBL-EK compared with those due to non-ESBL-EK. Cases were defined as patients with liver
cirrhosis and SBP due to ESBL-EK isolated from ascites. Control patients with liver cirrhosis and SBP due
to non-ESBL-EK were matched in a 3:1 ratio to cases according to the following five variables: age (± 5
years); gender; species of infecting organism; Child-Pugh score (± 2); Acute Physiological and Chronic
Health Evaluation II score (± 2). 'Effective initial therapy' was defined as less than 72 hours elapsing
between the time of obtaining a sample for culture and the start of treatment with an antimicrobial agent
to which the EK was susceptible. Cephalosporin use for ESBL-EK was considered 'ineffective', irrespective
of the minimum inhibitory concentration. ESBL production was determined according to the Clinical and
Laboratory Standards Institute guidelines on stored isolates.
Results: Of 1026 episodes of SBP in 958 patients from Jan 2000 through Dec 2006, 368 (35.9%) episodes
in 346 patients were caused by SBP due to EK, isolated from ascites. Of these 346 patients, twenty-six
(7.5%) patients with SBP due to ESBL-EK were compared with 78 matched controls. Treatment failure,
evaluated at 72 hours after initial antimicrobial therapy, was greater among the cases (15/26, 58% vs. 10/
78, 13%, P = .006); 30-day mortality rate was also higher than in the controls (12/26, 46% vs. 11/78, 15%,
P = .001). When the case were classified according to the effectiveness of the initial therapy, 'ineffective
initial therapy' was associated with higher 30-day mortality rate (11/18, 61% vs. 1/8, 13%, P = .036).
Conclusion: SBP due to ESBL-EK had poorer outcomes than SBP due to non-ESBL-EK. Ineffective initial
therapy seems to be responsible for the higher rate of treatment failure and mortality in SBP due to ESBL-
EK.
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Background
Spontaneous bacterial peritonitis (SBP) is a major cause
of morbidity and mortality in cirrhosis patients [1]. Gram
negative bacilli, such as Escherichia coli and Klebsiella spe-
cies (EK) are the most common cause of SBP [2,3]. Histor-
ically, early diagnosis using criteria based on ascitic
polymorphonuclear leukocyte count and empirical treat-
ment with effective antibiotics have improved the clinical
outcome of SBP [4-6]. 3rd generation cephalosporins, such
as cefotaxime, have been viewed as the drug of choice for
empirical treatment of SBP [3,6,7].
Since the 1980s, the incidence of infections due to
extended-spectrum β-lactamase-producing Escherichia coli
and  Klebsiella  species (ESBL-EK) has increased. Several
studies of clinical outcomes in patients with infections
due to ESBL-producing organisms have shown higher
mortality and reduced rates of clinical and microbiologic
response compared to infections due to non-ESBL-pro-
ducing organisms [8-12]. However the impact of ESBL-
producing organisms on clinical outcome has not been
well described in patients with SBP and advanced liver cir-
rhosis. We conducted the current study to evaluate the
outcomes of SBP due to ESBL-EK, based on their isolation
from ascites, compared with those of SBP due to non-
ESBL-EK. We also investigated the impact of ineffective
initial antimicrobial therapy on outcome in patients with
SBP due to ESBL-EK, and the risk factors for infection by
ESBL-producing microorganisms.
Methods
Patients
To identify patients with advanced liver cirrhosis and SBP
due to EK isolated from ascites, we reviewed the database
at the clinical microbiology laboratory, and the medical
records, by the diagnosis at discharge from 1 Jan 2000 to
31 Dec 2006. EK which was not susceptible to either cefo-
taxime or ceftazidime was considered 'suspected ESBL-
EK'. This study was approved by the institutional review
board by Seoul National University Hospital.
Microbiologic methods
Most of the ascitic isolates were collected by the clinical
microbiology laboratory in our hospital. Species identifi-
cation was carried out by standard methods with VITEK-
GNI cards (bioMerieux, Hazelwood, Mo.).
The antibiotic susceptibility of each isolate was deter-
mined by the disk diffusion method, using the criteria of
the Clinical and Laboratory Standards Institute (CLSI).
ESBL production was determined by the disk diffusion
method according to CLSI performance standards. Briefly,
we determined the diameters of the inhibition zones on
cefotaxime and ceftazidime disks (30 μg each), alone and
in combination with clavulanic acid (10 μg). An increase
of ≥5 mm in zone diameter when either of the antimicro-
bial agents was combined with clavulanic acid was con-
sidered evidence of ESBL production. Two control
organisms, E. coli ATCC 25922 and K. pneumoniae ATCC
700603, were inoculated in each set of tests for quality
control.
Definitions and data collection
Cases were defined as patients with advanced liver cirrho-
sis and SBP due to ESBL-EK, isolated from ascites. Con-
trols were patients with advanced liver cirrhosis and SBP
due to non-ESBL-EK. They were matched in a 3:1 ratio to
case patients according to the following five variables: age
(± 5 years); gender; species of infecting organism; Child-
Pugh score (± 2) [13]; Acute Physiological and Chronic
Health Evaluation (APACHE) II score (± 2) [14]. If more
than three patients were selected for candidate of control,
we chose three patients who had a Child-Pugh score close
to that of the case patient.
We reviewed the medical records of both case and control-
patients. The data collected included: age, gender, species
of infecting organism, Child-Pugh score, severity of illness
calculated by the APACHE II score, presentation with sep-
tic shock, presence of bacteremia, care in the intensive care
unit (ICU) and antimicrobial regimen. The following con-
ditions were also documented to identify 'risk factors' for
infection by ESBL-producing microorganism: hospital
stay before onset of SBP, presence of hepatocellular carci-
noma, history of SBP, antimicrobial therapy within the 30
days prior to onset of SBP, neutropenia, presence of cen-
tral venous catheter, indwelling urinary catheter, use of
immunosuppressive agents including corticosteroid
within 30 days, polymicrobial infection and invasive pro-
cedure within 72 hours prior to SBP.
Primary outcomes were the initial treatment response,
and 7-day and 30-day mortality rates. The initial treat-
ment response was assessed 72 hours after starting antimi-
crobial therapy and was classified as follows: 'complete
response' for patients who had resolution of fever, leuko-
cytosis and all signs of infection; 'partial response' for
patients who had abatement of abnormalities in the
above parameters without complete resolution; 'failure'
for patients who had died or deterioration or absence of
abatement of fever, leukocytosis and all other signs of
infection [10].
The diagnosis of SBP was based on the combination of a
positive ascitic fluid culture and a polymorphonuclear
leukocyte (PMNL) count of >250 cells/μL, or on a combi-
nation of symptoms/signs of SBP and a PMNL count of
>250 cells/μL [15]. Neutropenia was defined as an abso-
lute neutrophil count below 500/μL.BMC Infectious Diseases 2009, 9:41 http://www.biomedcentral.com/1471-2334/9/41
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'Effective initial therapy' was defined as less than 72 hours
elapsing between the time of obtaining a sample for cul-
ture and initiation of treatment with an 'effective' antimi-
crobial agent. The antimicrobial therapy was considered
'effective' if the treatment regimen included antibiotics
active in vitro, and the dosage and route of administration
were in conformity with current medical standards.
Cephalosporin monotherapy for ESBL-EK was considered
'ineffective', irrespective of the minimum inhibitory con-
centration.
Statistical analyses
The Pearson chi-square test, Fisher's exact test, Wilcoxon
signed rank test and Kaplan-Meier survival analysis were
used to compare clinical variables and outcomes, as
appropriate. All P values were two-tailed, with P < 0.05
being considered statistically significant. We performed
univariate analysis for the relationship between risk fac-
tors and infection by ESBL-producing EK using condi-
tional logistic regression. SPSS software version 15.0
(SPSS Inc, Chicago, IL) was used for these analyses.
Results
Study populations
From 1 Jan 2000 to 31 Dec 2006, 1026 episodes of SBP
were identified in 958 patients. Of the 1026 episodes, 368
(35.9%) in 346 patients were diagnosed as SBP due to EK
isolated from ascites. Of the 368 episodes, 32 (8.7%) were
due to 'suspected ESBL-EK'. All 32 strains of 'suspected
ESBL-EK' were stored, and all but one were recovered.
Each 'suspected ESBL-EK' caused one episode of SBP in
one patient. We performed a confirmatory test for ESBL-
production on these 31 EKs. Twenty-six were confirmed as
producing ESBL. These 26 patients were included in the
case group and the triple number of patients was selected
for the control group. Clinical characteristics including
five matched-variables in these patients are shown in
Table 1.
Clinical outcomes
Clinical outcomes and survival curves for SBP are shown
in Table 2 and Figure 1. The treatment failure rate of the
case patients, assessed 72 hours after initial therapy, was
higher than that of the control patients (58% vs. 13%, P =
.006). The 30-day mortality rate of the cases was also
higher than that of the controls (46% vs. 14%, P = .001).
Of the 26 case patients, eight (31%) had effective initial
therapy with imipenem, whereas all of the control
patients received effective initial therapy with 3rd genera-
tion cephalosporin. Of the 18 case patients who had inef-
fective initial therapy, two died within 72 hours of the
start of the empirical treatment. Apart for these two
patients, the remaining 16 patients received antibiotics
(carbapenems) effective against ESBL-EK after receipt of
reports of the susceptibility tests. The clinical characteris-
tics and outcomes of the patients with SBP due to ESBL-EK
are shown in Table 3 as a function of the effectiveness of
the initial therapy. In the cases, the treatment failure rate
and 30-day mortality rate of cases receiving effective ini-
tial therapy were significantly lower than those of patients
receiving ineffective initial therapy (13% vs. 61%, P  =
.036).
Risk factors for SBP due to ESBL-EK
The risk factors associated with SBP due to ESBL-EK are
listed in Table 4. No patient among either the cases or
controls had neutropenia, central venous catheter, immu-
nosuppressive agents, polymicrobial infection, or invasive
procedure within 72 hours. From a univariate analysis
using conditional logistic regression, hospital stay (≥2
weeks) before onset of SBP, previous history of SBP and
prior use of any antibiotics within 30 days were significant
factors associated with infection by ESBL-EK.
Discussion
In a previous study [16], we demonstrated that ESBL pro-
duction adversely affected clinical outcomes in bacteremic
SBP due to EK. However, because bacteremia is a more
Table 1: Clinical characteristics of patients with spontaneous bacterial peritonitis (SBP)
Clinical characteristics SBP due to P-value
ESBL-EK (n = 26) Non-ESBL-EK (n = 78)
Age (mean in year, SD) 59.5 ± 10.0 60.0 ± 9.7 0.799
Male (n, %) 19 (73%) 57 (73%) -
Escherichia coli (n, %) 17 (65%) 51 (65%) -
Child-Pugh score (mean, SD) 10.8 ± 1.6 10.6 ± 1.8 0.582
APACHE II score (mean, SD) 15.6 ± 3.7 15.3 ± 3.5 0.710
ESBL-EK – extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species
SD – standard deviation
APACHE II – Acute Physiologic and Chronic Health Evaluation II
ICU – intensive care unitBMC Infectious Diseases 2009, 9:41 http://www.biomedcentral.com/1471-2334/9/41
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severe infection and can be an independent poor prognos-
tic factor for SBP [17], we cannot extrapolate the results of
the previous study to SBP without bacteremia. Therefore,
we conducted the current study to evaluate the outcomes
of SBP due to ESBL-EK based on isolation from ascites,
compared with those of SBP due to non-ESBL-EK.
In patients with liver cirrhosis, Child-Pugh and APACHE
II scores are known to be the most important factors influ-
encing mortality due to SBP [1]. We tried to minimize the
confounding effects of Child-Pugh and APACHE II scores
by using matched controls. In addition we matched other
potential factors influencing the outcome of SBP: age,
gender, and species of infecting microorganism. Even after
matching these five important confounders, we found
that SBP due to ESBL-EK had poorer outcomes than SBP
due to non-ESBL-EK.
Among the other factors influencing the outcomes of
ESBL infection, the impact of a delay in effective initial
treatment was controversial. Lautenbach et al. and our
previous work showed that a delay in effective treatment
for ESBL-producing organisms did not result in poorer
clinical outcomes in patients with urinary tract and blood-
stream infections generally originating from the pancrea-
tobiliary tract [10,18]. In contrast, in patients with non-
urinary infections, Hyle et al. demonstrated that inade-
quate initial therapy was an independent risk factor for
mortality in ESBL-EK infections [19]. In the current study,
there was no statistically significant effect of the five major
confounders, and ineffective initial treatment was associ-
ated with higher initial treatment failure and 30-day mor-
tality rate, despite the use of effective carbapenems once
the reports of the susceptibility of the microorganisms
had been received.
Therefore, it would seem reasonable to treat patients with
SBP due to ESBL-EK with effective antibiotics straight
away. However, SBP due to ESBL-EK accounted for only
7.5% (26/346) of the SBP due to EK, and the injudicious
use of broad antimicrobial regimens is likely to result in
further emergence of resistance. We suggest that one
should use antibiotics active against ESBL-producing
organisms in those selected patients who have a high risk
of infection. The risk factors for the development of infec-
tion with ESBL-producing organisms that have been listed
in previous studies are: length of hospital stay and ICU
stay, presence of central venous catheter, prior administra-
tion of an antibiotic, and severity of illness etc
[10,11,18,20,21]. In the current study, univariate analysis
using conditional logistic regression showed that hospital
stay (≥2 weeks) before onset of SBP, previous history of
SBP and prior use of any antibiotics within 30 days were
Survival curves obtained by the Kaplan-Meier method Figure 1
Survival curves obtained by the Kaplan-Meier 
method. Survival curves for spontaneous bacterial peritoni-
tis (SBP) due to Escherichia coli and Klebsiella species (EK), as a 
function of the production of extended-spectrum β-lacta-
mase (ESBL). The P values shown were calculated by the log 
rank test.
Table 2: Clinical outcomes of patients with spontaneous bacterial peritonitis (SBP) due to Escherichia coli and Klebsiella species (EK), 
according to the production of extended-spectrum β-lactamase (ESBL)
Outcomes SBP due to P-value
ESBL-EK (n = 26) Non-ESBL-EK (n = 78)
Initial response†
Complete response (n, %) 2 (8%) 28 (36%) < 0.001
Treatment failure (n, %) 15 (58%) 10 (13%) 0.006
7-day mortality (n, %) 9 (35%) 3 (4%) < 0.001
30-day mortality (n, %) 12 (46%) 11 (14%) 0.001
† Initial response was assessed 72 hours after the initiation of empirical treatmentBMC Infectious Diseases 2009, 9:41 http://www.biomedcentral.com/1471-2334/9/41
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significantly associated factors for ESBL-EK infections. To
promote the prudent use of antimicrobial agents, we need
further efforts to identify the risk factors for ESBL infec-
tion, as well as to optimize initial therapy [22].
Our study has potential limitations. First, we did not eval-
uate the 'attributable' mortality of SBP; some deaths in
our study may not have been related to the SBP. However,
efforts to designate outcomes as 'attributable' to infection
are often subjective and inconsistent [19,23]. We there-
fore employed unambiguous definitions, namely in-hos-
pital mortality rates (7-day, 30-day) as the primary
outcomes. Second, because the present study was retro-
spective and non-randomized, there was potential for
confounding and bias due to unknown factors during the
selection of patients and analysis of the results. However,
all case and control patients were selected from the same
microbiology laboratory in the same hospital, and they
were matched according to the defined criteria. The poten-
tial for selection bias and confounding effects should
therefore be small. Finally, the small sample size limited
our capacity to identify risk factors for infection with
ESBL-producing EK using multivariate analysis. Moreover
the univariate analysis should be interpreted with caution
because of possible confounding effect of unidentified
risk factors.
Table 3: Characteristics and outcomes of patients with spontaneous bacterial peritonitis due to extended-spectrum β-lactamase-
producing Escherichia coli and Klebsiella species (ESBL-EK), according to the effectiveness of the initial therapy
Characteristics Initial therapy P-value
Effective (n = 8) Ineffective (n = 18)
Age (mean in year, SD) 62.1 ± 9.3 58.3 ± 10.4 0.363
Male (n, %) 4 (50%) 15 (83%) 0.149
Escherichia coli (n, %) 5 (63%) 12 (67%) 1.000
Child-Pugh score (mean, SD) 10.4 ± 1.6 11.1 ± 1.6 0.330
APACHE II score (mean, SD) 15.6 ± 3.8 15.6 ± 3.7 0.993
Outcomes
Initial response†
Complete response (n, %) 1 (13%) 1 (6%) 0.529
Treatment failure (n, %) 2 (25%) 13 (72%) 0.038
7-day mortality (n, %) 1 (13%) 8 (44%) 0.190
30-day mortality (n, %) 1 (13%) 11 (61%) 0.036
SD – standard deviation
APACHE II – Acute Physiologic and Chronic Health Evaluation II
† Initial response was assessed 72 hours after the initiation of empirical treatment
Table 4: Risk factors for spontaneous bacterial peritonitis (SBP) due to extended-spectrum β-lactamase-producing Escherichia coli and 
Klebsiella species (ESBL-EK)
Risk factors SBP due to OR (95% CI)
ESBL-EK
(n = 26)
Non-ESBL-EK
(n = 78)
Hospital stay before onset of SBP 23.3 ± 24.8 1.6 ± 5.0 -
(mean in days, SD)
≥ 2 weeks (n, %) 13 (50%)   3 (4%)   35.11 (4.57 to 269.72)  
Presence of hepatocellular carcinoma (n, %) 9 (35%) 21 (27%) 1.46 (0.55 to 3.94)
Presentation with septic shock (n, %) 11 (42%) 22 (28%) 2.21 (0.78 to 6.31)
Presence of bacteremia (n, %) 5 (19%) 13 (17%) 1.16 (0.41 to 3.33)
ICU care (n, %) 5 (19%) 7 (9%) 2.53 (0.70 to 9.12)
Previous history of SBP (n, %) 19 (73%) 23 (30%) 12.91 (2.88 to 57.76)
Prior use of antibiotics within 30 days† (n, %) 21 (81%) 13 (17%) 15.13 (4.44 to 51.52)
SD – standard deviation
OR – odds ratio
CI – confidence interval
†All the patients with a history of use of antibiotics had received 3rd generation cephalosporins within 30 days before the onset of SBP.BMC Infectious Diseases 2009, 9:41 http://www.biomedcentral.com/1471-2334/9/41
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Conclusion
Our results indicated that SBP due to ESBL-EK had poorer
outcomes than SBP due to non-ESBL-EK and 'ineffective
initial therapy' may be a cause of the higher rates of treat-
ment failure and mortality in SBP due to ESBL-EK. How-
ever, SBP due to ESBL-EK accounted for only 7.5% (26/
346) of the SBP due to EK, and the imprudent use of
broad spectrum antibiotics should be avoided. Therefore,
studies aimed at identifying the risk factors for SBP caused
by ESBL-producing organism are needed in order to opti-
mize initial therapy for selected patients who have a high
risk of infection.
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